Trial Profile
A single site, open-label phase I trial of NDI 010976 in healthy volunteers.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2016
Price :
$35
*
At a glance
- Drugs Firsocostat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nimbus Therapeutics
- 04 Apr 2016 According to a Gilead Sciences media release, the results of this trial will be presented at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).
- 24 Apr 2015 New trial record